Targeting the DNA damage response in immuno-oncology: developments and opportunities
Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …
outcome with regard to multiple tumour types. However, most patients still do not benefit …
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis
EC Lerner, KI Woroniecka, VM D'Anniballe… - Nature Cancer, 2023 - nature.com
The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell
killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell …
killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell …
A second-generation M1-polarized CAR macrophage with antitumor efficacy
A Lei, H Yu, S Lu, H Lu, X Ding, T Tan, H Zhang… - Nature …, 2024 - nature.com
Chimeric antigen receptor (CAR) T cell therapies have successfully treated hematological
malignancies. Macrophages have also gained attention as an immunotherapy owing to their …
malignancies. Macrophages have also gained attention as an immunotherapy owing to their …
Restoring tumor immunogenicity with dendritic cell reprogramming
Decreased antigen presentation contributes to the ability of cancer cells to evade the
immune system. We used the minimal gene regulatory network of type 1 conventional …
immune system. We used the minimal gene regulatory network of type 1 conventional …
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
Advancing CAR T cell therapy through the use of multidimensional omics data
Despite the notable success of chimeric antigen receptor (CAR) T cell therapies in the
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
Bodywide ecological interventions on cancer
Historically, cancer research and therapy have focused on malignant cells and their tumor
microenvironment. However, the vascular, lymphatic and nervous systems establish long …
microenvironment. However, the vascular, lymphatic and nervous systems establish long …
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy produces high response
rates and durable remissions in patients with large B-cell lymphoma (LBCL), relapses can …
rates and durable remissions in patients with large B-cell lymphoma (LBCL), relapses can …